Outcomes

The available evidence for follistatin 315 outcomes is extremely limited and consists primarily of preclinical animal studies and in vitro research. No clinical trials specifically evaluating follistatin 315 in humans were identified.

Reported Outcomes from Animal Studies

Musculoskeletal Effects:

In young adult male mice, follistatin-induced muscle growth was associated with altered bone geometry, suggesting potential effects on the musculoskeletal system beyond muscle tissue alone (PMID: 33869993)
In vitro studies reported effects on migration, vascularization, and osteogenesis, with some evidence for bone repair promotion in animal models (PMID: 30881954)

Reproductive/Developmental Effects:

Limited evidence from pig embryo studies suggested effects on pre-implantational development in parthenogenetic embryos (PMID: 29119699)

Pharmacokinetic Properties:

Research on follistatin-Fc fusion proteins indicated that glycosylation patterns significantly impact pharmacokinetic behavior, though this relates to modified versions rather than native follistatin 315 (PMID: 26354950)

Strength of Evidence

The evidence base is very weak. Key limitations include:

No human clinical data available
Small number of relevant studies
Primarily preclinical and in vitro research
No standardized outcome measures across studies
Unclear generalizability from animal models to human applications

Safety Considerations

One study identified follistatin 344 (a related compound) in black market products, raising concerns about unregulated use and quality control (PMID: 31758732).

Disclaimer: This information is for research purposes only and should not be used for medical decision-making. Consult healthcare professionals for medical advice regarding any therapeutic interventions.

The current evidence is insufficient to draw meaningful conclusions about clinical outcomes or therapeutic benefits of follistatin 315 in humans.

Follistatin 315

Member access required